# From Biological Waste to Therapeutic Resources: A Comprehensive Review of Stem Cell Sources, Characterization, and Biomedical Potentials

## TL;DR

This paper reviews how stem cells from biological waste can be used for regenerative medicine, offering ethical and cost-effective alternatives to traditional methods.

## Contribution

The paper provides a comprehensive review of waste-derived stem cell sources and their biomedical potential, emphasizing recent advances and regulatory challenges.

## Key findings

- Stem cells from waste materials show robust proliferation and differentiation potential for regenerative medicine.
- Clinical trials report up to 30–40% improvement in recovery for osteoarthritis and ischemic heart disease using waste-derived stem cells.
- Regulatory agencies classify some processing methods as 'more-than-minimal manipulation,' slowing clinical adoption.

## Abstract

The concept of utilizing biological waste as a resource dates back centuries, with early practices in traditional medicine repurposing discarded tissues for healing purposes. In recent decades, advances in stem cell biology have revitalized this concept by identifying multipotent stem cells within various waste materials, including urine, adipose tissue, follicular fluid, umbilical cord blood, fetal annexes, menstrual blood, and dental pulp byproducts. These sources offer a minimally invasive, ethically sound, and cost-effective alternative to conventional stem cell harvesting methods. Stem cells derived from waste materials exhibit robust proliferative abilities and multilineage differentiation potential, positioning them as valuable tools for regenerative medicine, tissue engineering, and personalized therapeutic applications. Clinical studies highlight their promise. For example, mesenchymal stem cells from adipose tissue and umbilical cord blood have shown safety and some effectiveness in early trials. These studies report improvements of up to 30–40% in recovery scores for osteoarthritis and ischemic heart disease, as well as a 20–35% decrease in inflammatory markers for autoimmune disorders. Cord blood stem cell transplants have shown 70–90% survival rates in children with blood cancers. This underscores the clinical potential of waste-derived stem cells. However, regulatory issues limit broader use. Agencies like the U.S. Food and Drug Administration and the European Medicines Agency classify many processing methods, especially enzymatic digestion, as “more-than-minimal manipulation.” This triggers strict requirements for Good Manufacturing Practice, clinical validation, and safety checks. These rules protect donors, ensure consistency, and check long-term safety. However, they also slow down clinical adoption. This review describes the history and recent advances in recycling biological waste to obtain stem cells, operating within the theoretical framework that positions waste-derived materials as viable sources for regenerative medicine. It highlights how these developments are transforming biomedical research and clinical care.

The online version contains supplementary material available at 10.1007/s12015-025-10989-3.